Search research articles
Contact Us
Filters
Showing results (61-70 of 109) with videos related to
Page
of 11
Sort By:
Molecular Pharmaceutics
|
December 1, 2025
Longitudinal [<sup>18</sup>F]FMISO PET Evaluation of Hypoxic Tissue in a Rat Model of Hindlimb Ischemia
Noemí Gómez-Lado, David Rey-Bretal, Manuel Piñeiro-Fiel, et al.
The Journal of Infectious Diseases
|
January 16, 2016
Vaccination Against Hepatitis B Virus (HBV) in HIV-1-Infected Patients With Isolated Anti-HBV Core Antibody: The ANRS HB EP03 CISOVAC Prospective Study
Lionel Piroth, Odile Launay, Marie-Louise Michel, et al.
JAMA
|
April 14, 2011
Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial
Odile Launay, Diane van der Vliet, Arielle R Rosenberg, et al.
Scandinavian Journal of Infectious Diseases
|
September 18, 2014
Efficacy and safety of switching to raltegravir plus atazanavir dual therapy in pretreated HIV-1-infected patients over 144 weeks: a cohort study
Pierre Gantner, Christine Koeppel, Marialuisa Partisani, et al.
Journal of Hepatology
|
June 3, 2014
Role of a 48-week pegylated interferon therapy in hepatitis B e antigen positive HIV-co-infected patients on cART including tenofovir: EMVIPEG study
Patrick Miailhes, Marianne Maynard-Muet, Fanny Lebossé, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
July 1, 2018
Hepatitis C virus incidence in HIV-infected and in preexposure prophylaxis (PrEP)-using men having sex with men
Laurent Cotte, Eric Cua, Jacques Reynes, et al.
Plos One
|
October 22, 2015
Potential for Drug-Drug Interactions between Antiretrovirals and HCV Direct Acting Antivirals in a Large Cohort of HIV/HCV Coinfected Patients
Isabelle Poizot-Martin, Alissa Naqvi, Véronique Obry-Roguet, et al.
The Journal of Antimicrobial Chemotherapy
|
October 15, 2021
Dolutegravir-based dual maintenance regimens combined with lamivudine/emtricitabine or rilpivirine: risk of virological failure in a real-life setting
Colin Deschanvres, Jacques Reynes, Isabelle Lamaury, et al.
Plos One
|
February 3, 2017
Effectiveness and tolerance of single tablet versus once daily multiple tablet regimens as first-line antiretroviral therapy - Results from a large french multicenter cohort study
Laurent Cotte, Tristan Ferry, Pascal Pugliese, et al.
The Journal of Antimicrobial Chemotherapy
|
December 16, 2017
Dolutegravir reshapes the genetic diversity of HIV-1 reservoirs
Pierre Gantner, Guinevere Q Lee, David Rey, et al.
Page
of 11
Search research articles
Search
Showing results (61-70 of 109) with videos related to
Sort By:
Page
of 11
Molecular Pharmaceutics
|
December 1, 2025
Longitudinal [<sup>18</sup>F]FMISO PET Evaluation of Hypoxic Tissue in a Rat Model of Hindlimb Ischemia
Noemí Gómez-Lado, David Rey-Bretal, Manuel Piñeiro-Fiel, et al.
The Journal of Infectious Diseases
|
January 16, 2016
Vaccination Against Hepatitis B Virus (HBV) in HIV-1-Infected Patients With Isolated Anti-HBV Core Antibody: The ANRS HB EP03 CISOVAC Prospective Study
Lionel Piroth, Odile Launay, Marie-Louise Michel, et al.
JAMA
|
April 14, 2011
Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial
Odile Launay, Diane van der Vliet, Arielle R Rosenberg, et al.
Scandinavian Journal of Infectious Diseases
|
September 18, 2014
Efficacy and safety of switching to raltegravir plus atazanavir dual therapy in pretreated HIV-1-infected patients over 144 weeks: a cohort study
Pierre Gantner, Christine Koeppel, Marialuisa Partisani, et al.
Journal of Hepatology
|
June 3, 2014
Role of a 48-week pegylated interferon therapy in hepatitis B e antigen positive HIV-co-infected patients on cART including tenofovir: EMVIPEG study
Patrick Miailhes, Marianne Maynard-Muet, Fanny Lebossé, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
July 1, 2018
Hepatitis C virus incidence in HIV-infected and in preexposure prophylaxis (PrEP)-using men having sex with men
Laurent Cotte, Eric Cua, Jacques Reynes, et al.
Plos One
|
October 22, 2015
Potential for Drug-Drug Interactions between Antiretrovirals and HCV Direct Acting Antivirals in a Large Cohort of HIV/HCV Coinfected Patients
Isabelle Poizot-Martin, Alissa Naqvi, Véronique Obry-Roguet, et al.
The Journal of Antimicrobial Chemotherapy
|
October 15, 2021
Dolutegravir-based dual maintenance regimens combined with lamivudine/emtricitabine or rilpivirine: risk of virological failure in a real-life setting
Colin Deschanvres, Jacques Reynes, Isabelle Lamaury, et al.
Plos One
|
February 3, 2017
Effectiveness and tolerance of single tablet versus once daily multiple tablet regimens as first-line antiretroviral therapy - Results from a large french multicenter cohort study
Laurent Cotte, Tristan Ferry, Pascal Pugliese, et al.
The Journal of Antimicrobial Chemotherapy
|
December 16, 2017
Dolutegravir reshapes the genetic diversity of HIV-1 reservoirs
Pierre Gantner, Guinevere Q Lee, David Rey, et al.
Page
of 11